Cargando…
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial cells by using the spike protein on its surface to bind to angiotensin-converting enzyme 2 receptor on the cells. Thus, can...
Autor principal: | Tumban, Ebenezer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824305/ https://www.ncbi.nlm.nih.gov/pubmed/33396343 http://dx.doi.org/10.3390/v13010054 |
Ejemplares similares
-
Virus-like Particle Vaccines and Platforms for Vaccine Development
por: Kheirvari, Milad, et al.
Publicado: (2023) -
Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature
por: Peabody, Julianne, et al.
Publicado: (2017) -
Approved mRNA Vaccines for SARS-CoV-2
por: Faiman, Beth
Publicado: (2021) -
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
por: Yadav, Rashi, et al.
Publicado: (2019) -
Insights from the Construction of Adenovirus-Based Vaccine Candidates against SARS-CoV-2: Expecting the Unexpected
por: Weklak, Denice, et al.
Publicado: (2023)